Close Menu

NEW YORK (GenomeWeb) – The Japanese Ministry of Health, Labor, and Welfare has granted manufacturing and marketing approval for Myriad Genetics' BRACAnalysis Diagnostic System.

The test is approved as a companion diagnostic that can determine which metastatic, inoperable, or recurrent breast cancer patients have BRCA1 and BRCA2 genetic mutations, and therefore will likely to respond to the PARP inhibitor Lynparza (olaparib). Myriad will partner with Miraca Group subsidiary SRL, a large laboratory services provider in Japan, to commercialize BRACAnalysis in the country.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.

A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.

The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.

In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.